FDA warned API supplier Darmerica, LLC (Davie, FL) after a March 2025 inspection found CGMP failures that render its drug APIs adulterated, plus misbranding violations including distribution of APIs ineligible for 503A compounding. The letter specifically cites the firm's drug listing for Hexarelin Acetate (NDC 71052-621), which reported an incorrect active peptide ingredient. It ties the misbranding to products distributed for compounding use.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.